Pharmacoeconomic Analysis of Medicines Used for Bronchial Asthma in Children in Kazakhstan.

Journal of mother and child Pub Date : 2025-05-24 eCollection Date: 2025-02-01 DOI:10.34763/jmotherandchild.20252901.d-24-00046
Elmira Serikbayeva, Nizom Suyunov, Baurzhan Makhatov, Ainash Atimtaikyzy, Aigul Ibragimova, Maksuda Abdullaeva
{"title":"Pharmacoeconomic Analysis of Medicines Used for Bronchial Asthma in Children in Kazakhstan.","authors":"Elmira Serikbayeva, Nizom Suyunov, Baurzhan Makhatov, Ainash Atimtaikyzy, Aigul Ibragimova, Maksuda Abdullaeva","doi":"10.34763/jmotherandchild.20252901.d-24-00046","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>This study aimed to calculate a pharmacoeconomic indicator, specifically the cost-effectiveness coefficient, for treating paediatric bronchial asthma with combined regimens of bronchodilators and inhaled corticosteroids.</p><p><strong>Material and methods: </strong>This study involves 54 children aged 6 to 12 years, who were divided into 6 groups depending on the age and severity of bronchial asthma. Treatment effectiveness is calculated by subtracting the percentage difference between exacerbation frequency and the number of patients. The calculation of pharmacoeconomic data was conducted using the cost-effectiveness ratio (CER).</p><p><strong>Results: </strong>For the treatment of mild bronchial asthma, the drug Berodual is used for inhalation through a nebuliser, moderate therapy is conducted using a combination of Flixotide and Salbutamol, and severe is stopped by a combination of Symbicort and Salbutamol. From the results obtained, notably, the CER for mild severity was 0.077 for children aged 6-8 years and 0.171 for the age group 9-12 years; for moderate severity, the CER values were 0.27 for the group 6-8 years and 0.35 for the category 9-12 years; severe asthma had the following indicators: 0.506 and 0.798 for groups aged 6-8 and 9-12, respectively.</p><p><strong>Conclusion: </strong>This study's results indicate that the most cost-effective treatment regimen is in the age groups of 6-8 years. However, the calculation of drug dosages directly depends on the patient's age and the severity of the disease. Further actions in scientific works should be directed to conducting empirical, statistical studies in the field of pharmacoeconomics of bronchial asthma among children from the standpoint of the state.</p>","PeriodicalId":73842,"journal":{"name":"Journal of mother and child","volume":"29 1","pages":"20-29"},"PeriodicalIF":0.0000,"publicationDate":"2025-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of mother and child","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.34763/jmotherandchild.20252901.d-24-00046","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: This study aimed to calculate a pharmacoeconomic indicator, specifically the cost-effectiveness coefficient, for treating paediatric bronchial asthma with combined regimens of bronchodilators and inhaled corticosteroids.

Material and methods: This study involves 54 children aged 6 to 12 years, who were divided into 6 groups depending on the age and severity of bronchial asthma. Treatment effectiveness is calculated by subtracting the percentage difference between exacerbation frequency and the number of patients. The calculation of pharmacoeconomic data was conducted using the cost-effectiveness ratio (CER).

Results: For the treatment of mild bronchial asthma, the drug Berodual is used for inhalation through a nebuliser, moderate therapy is conducted using a combination of Flixotide and Salbutamol, and severe is stopped by a combination of Symbicort and Salbutamol. From the results obtained, notably, the CER for mild severity was 0.077 for children aged 6-8 years and 0.171 for the age group 9-12 years; for moderate severity, the CER values were 0.27 for the group 6-8 years and 0.35 for the category 9-12 years; severe asthma had the following indicators: 0.506 and 0.798 for groups aged 6-8 and 9-12, respectively.

Conclusion: This study's results indicate that the most cost-effective treatment regimen is in the age groups of 6-8 years. However, the calculation of drug dosages directly depends on the patient's age and the severity of the disease. Further actions in scientific works should be directed to conducting empirical, statistical studies in the field of pharmacoeconomics of bronchial asthma among children from the standpoint of the state.

哈萨克斯坦儿童支气管哮喘用药的药物经济学分析。
背景:本研究旨在计算支气管扩张剂和吸入皮质类固醇联合治疗小儿支气管哮喘的药物经济学指标,特别是成本-效果系数。材料与方法:本研究纳入54例6 ~ 12岁儿童,根据年龄和支气管哮喘严重程度分为6组。治疗效果是通过减去恶化频率和患者数量之间的百分比差来计算的。采用成本-效果比(CER)计算药物经济学数据。结果:治疗轻度支气管哮喘时,使用雾化器吸入药物贝罗双,中度应用氟替肽联合沙丁胺醇治疗,重度应用辛比可联合沙丁胺醇治疗。从获得的结果来看,值得注意的是,6-8岁儿童轻度严重程度的CER为0.077,9-12岁儿童为0.171;对于中度严重程度,6-8岁组的CER值为0.27,9-12岁组的CER值为0.35;6-8岁和9-12岁重度哮喘的指标分别为0.506和0.798。结论:本研究结果表明,6-8岁年龄组是最具成本效益的治疗方案。然而,药物剂量的计算直接取决于患者的年龄和疾病的严重程度。科学工作的进一步行动应该从国家的角度出发,在儿童支气管哮喘的药物经济学领域进行实证和统计研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.30
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信